1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Drugs In Development, 2022, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 46, 48, 53, 6, 109, 37 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 23 and 7 molecules, respectively.
Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hypertension - Overview
- Hypertension - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hypertension - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypertension - Companies Involved in Therapeutics Development
- Hypertension - Drug Profiles
- Hypertension - Dormant Projects
- Hypertension - Discontinued Products
- Hypertension - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Hypertension, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hypertension - Dormant Projects, 2022
- Hypertension - Discontinued Products, 2022
- Number of Products under Development for Hypertension, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 35Pharma Inc
- Aadi Bioscience Inc
- Abivax SA
- Addpharma Inc
- Adepthera LLC
- Adhera Therapeutics Inc
- Advent Therapeutics Inc
- Aeon Respire Inc
- Aerami Therapeutics Inc
- Aerogen Pharma Corp
- Aerovate Therapeutics Inc
- Aggamin LLC
- Ahn-Gook Pharmaceutical Co Ltd
- AI Therapeutics Inc
- Ajanta Pharma Ltd
- Aju Pharm Co Ltd
- Alchemedicine Co Ltd
- Algorithm Sciences Inc
- Alnylam Pharmaceuticals Inc
- Altavant Sciences Inc
- Alterras Therapeutics GmbH
- Alveolus Bio Inc
- Amgen Inc
- Anagenics Ltd
- AnGes Inc
- Angion Biomedica Corp
- Antlia Bioscience Inc
- AOBiome LLC
- Apaxen
- APEIRON Biologics AG
- Apollo Therapeutics LLC
- APT Therapeutics Inc
- Aqualung Therapeutics Corp
- Argo Biopharma Australia Pty Ltd
- Arovella Therapeutics Ltd
- AstraZeneca Plc
- Attgeno AB
- ATXA Therapeutics Ltd
- Autotelic Bio Inc
- Avirmax Inc
- Bayer AG
- Bial - Portela & Ca SA
- Biogen Inc
- BioRestorative Therapies Inc
- Biozeus Pharmaceutical SA
- Boehringer Ingelheim International GmbH
- Boryung Pharmaceutical Co Ltd
- Brainfarma Chemical and Pharmaceutical Industry SA
- C4X Discovery Holdings Plc
- Camurus AB
- Capricor Therapeutics Inc
- CardioPharma Inc
- Cardiorentis AG
- CellionBioMed Inc
- Celltrion Inc
- Celon Pharma SA
- Celtaxsys Inc
- Centessa Pharmaceuticals Plc
- Cereno Scientific AB
- Chengdu Dikang Pharmaceuticals Co Ltd
- Chiesi Farmaceutici SpA
- Chong Kun Dang Pharmaceutical Corporation
- CinCor Pharma Inc
- Claritas Pharmaceuticals Inc
- Closed Loop Medicine Ltd
- Cloud Pharmaceuticals Inc
- Comanche Biopharma Corp
- Corsair Pharma Inc
- Cumberland Pharmaceuticals Inc
- D. Western Therapeutics Institute Inc
- Daewon Pharmaceutical Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Denovo Biopharma LLC
- Dilafor AB
- Dong-A ST Co Ltd
- DongKoo Bio & Pharma Co Ltd
- Dongkook Pharmaceutical Co Ltd
- Eldrug SA
- Eli Lilly and Co
- Excubio Pharmaceuticals Inc
- Fauna Bio
- Ferring Pharmaceuticals Inc
- FunPep Co Ltd
- Galectin Therapeutics Inc
- GenKyoTex SA
- GenThera Inc
- Genuone Science Co Ltd
- George Medicines Pty Ltd
- GEXVal Inc
- Gilead Sciences Inc
- Gmax Biopharm LLC
- Gossamer Bio Inc
- Guangdong East Sunshine Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Guangzhou Yipinhong Pharmaceutical Co Ltd
- H. Lundbeck AS
- Hanlim Pharm Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Hetero Drugs Ltd
- Himuka AM Pharma Corp
- HK inno.N Corp
- Huons Co Ltd
- Hyalos Therapeutics Inc
- Idorsia Pharmaceutical Ltd
- Ildong Pharmaceutical Co Ltd
- Imagine Pharma LLC
- Imunon Inc
- Innolife Co Ltd
- Innopharmax Inc
- Innovative Pharmacology Research
- Insmed Inc
- Interprotein Corp
- INVENT Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- JW Pharmaceutical Corp
- KARE Biosciences Inc
- KBP Biosciences Co Ltd
- Keros Therapeutics Inc
- Kolmar Korea Co Ltd
- Kuhnil Pharmaceutical Co Ltd
- Kyowa Kirin Co Ltd
- Kyung Dong Co Ltd
- Laboratorios Silanes SA de CV
- Larix Bioscience LLC
- Lempo Therapeutics Ltd
- Les Laboratoires Servier SAS
- Lexaria Bioscience Corp
- Liaoning Haiwang Biotechnoloty Co Ltd
- Liquidia Technologies Inc
- LTT Bio-Pharma Co Ltd
- Luckwel Pharmaceuticals Inc
- Lyndra Therapeutics Inc.
- Merck & Co Inc
- Mineralys Therapeutics Inc
- Morphic Therapeutic Inc
- NA Vaccine Research Institute Co Ltd
- Nadian Bio Ltd
- Nanjing Yoko Biomedical Co Ltd
- NeuroBo Pharmaceuticals Inc
- Nippon Shinyaku Co Ltd
- Nissan Chemical Corp
- Northern Therapeutics Inc
- Novartis AG
- NuSirt Biopharma Inc
- NVP Healthcare Co Ltd
- Omeros Corp
- Orion Corp
- Overseas Pharmaceuticals Ltd
- Panorama Researchama Research
- PharmaIN Corp
- Pharming Group NV
- Pharmosa Biopharm Inc
- PhaseBio Pharmaceuticals Inc
- PRM Pharma LLC
- Proteo Biotech AG
- PulmoSIM Therapeutics
- Q BioMed Inc
- Qanatpharma GmbH
- Quantum Genomics SA
- Radikal Therapeutics Inc
- Reata Pharmaceuticals Inc
- Recursion Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
- Renova Therapeutics Inc
- Respira Therapeutics Inc
- Resverlogix Corp
- Reviva Pharmaceuticals Inc
- Ribomic Inc
- RMJ Holdings LLC
- Samik Pharmaceutical Co Ltd
- Sanofi
- Sardocor Corp
- Sarfez Pharmaceuticals Inc
- Scohia Pharma Inc
- Shaanxi Micot Technology Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Pharmaceuticals Holding Co Ltd
- Shanghai Xinyi Pharmaceutical Co Ltd
- Shenzhen Evergreen Therapeutics Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shiftbio Co Ltd
- Shijiazhuang Sagacity New Drug Development Co Ltd
- Shin Poong Pharm Co Ltd
- Sirnaomics Ltd
- SJT Molecular Research SL
- Sorrento Therapeutics Inc
- SteadyMed Therapeutics Inc
- Structure Therapeutics Inc
- Sulfateq BV
- Synokem Pharmaceuticals Ltd
- Systimmune Inc
- Takeda Pharmaceutical Co Ltd
- Target Medicals
- Tenax Therapeutics Inc
- Theracos Inc
- Theravance Biopharma Inc
- Topadur Pharma AG
- Torrent Pharmaceuticals Ltd
- Translate Bio Inc
- Triastek Inc
- Tris Pharma Inc
- Tritech Biopharmaceuticals Co Ltd
- United Therapeutics Corp
- Vascular BioSciences
- Vasculonics LLC
- VasThera Co Ltd
- Vectus Biosystems Ltd
- Vicore Pharma AB
- Vifor Pharma Ltd
- Vivus LLC
- Voronoi Group
- Windtree Therapeutics Inc
- Worphmed Srl
- Wuhan Langlai Technology Development Co Ltd
- XuanZhu Biological Technology Co Ltd
- Yungjin Pharm Co Ltd
- Zumbro Discovery Inc
- Zuventus Healthcare Ltd
- Zymedi
